Molecular Imaging

With PET and single-photon emission computed tomography (SPECT), researchers have demonstrated that T cells can be modified with the antibody report 1 (DAbR1) gene to enable in vivo tracking for immunotherapy, according to research published in the Journal of Nuclear Medicine.

Positron emission tomography (PET) has historically been an afterthought in musculoskeletal imaging for many logical reasons, but authors of a new investigation believe the method should play a larger role in managing these patients.

New 2018 guidelines for myocardial perfusion imaging (MPI) protocols on conventional and novel single photon emission computed tomography (SPECT) for nuclear cardiology practitioners has received praise from the Society for Nuclear Medicine and Molecular Imaging (SNMMI).

A new molecular imaging system developed by researchers from the University of Illinois can show living tissue in great detail and may allow researchers to monitor cancerous cells as they progress inside the body.

Three international experts recently argued for a resolution to the salivary gland (SG) toxicity side effect seen in metastatic castration-resistant prostate cancer (mCRPC) patients treated with I-131 labeled PSMA radioligand therapies (PRLT).

Researchers from Sweden have developed a fully automated PET spatial normalization method for amyloid-β (Aβ) imaging that may reduce interpretation variability among readers and monitor the effectiveness of patients treated with anti-Aβ drugs—a promising step for Alzheimer’s research.

In a blow to Medicare patients with metastatic cancers, the Centers for Medicare & Medicaid Services (CMS) announced it has rejected reimbursement coverage for 18F-sodium fluoride positron emission tomography (NaF PET) imaging.

New guidelines for researchers wanting to study how molecules in the body use metals such as iron and magnesium to maintain good health have been established by researchers at the University of Virginia (UVA).

A team of scientists found therapeutic treatment using radiopharmaceutical I-131 mIBG can effectively mitigate symptoms of certain neuroendocrine tumors and resulted in improved prognosis for patients with symptomatic progression, radiographic response or stability and biochemical response.

A new discovery involving diamonds may significantly cut costs related to medical imaging and drug-discovery devices, according to a team of researchers led by the U.S. Department of Energy and the University of California, Berkeley. 

A team of German researchers used PET/CT and modeling practices to create a new method to pattern and predict tumor response in radioligand therapy (RLT), which authors say is the first attempt to do so.

The "disease screening pill," developed by researchers from the University of Michigan, lit up malignant tumors in mice when exposed to near-infrared light—all without the use of radiation, according to a study published in Molecular Pharmaceutics.